Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits

被引:37
作者
Zhao, SP [1 ]
Zhang, DQ [1 ]
机构
[1] Cent S Univ, Xiangya Hosp 2, Dept Cardiol, Changsha 410011, Peoples R China
关键词
atorvastatin; hypercholesterolemia; adipocytes; interleukin-6; PPAR gamma;
D O I
10.1016/S0009-8981(03)00335-8
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Interleukin-6 (IL-6) is secreted by adipocytes and may be involved in atherosclerosis. Few studies have assessed the influence of statins on IL-6 secretion in adipocytes. Methods: Rabbits on high-cholesterol diets were randomly given either atorvastatin 1.5 mg/kg day(-1) (n = 5) or starch (n = 5) for 2 weeks. Subcutaneous adipose was collected for adipocytes culture. IL-6 concentrations in plasma and adipocytes culture supernatant were measured by ELISA. RT-PCR was used to evaluate peroxisome proliferator-activated receptor (PPAR) gamma mRNA expression. The in vitro effect of atorvastatin on IL-6 production in adipocytes was observed. Results: Two weeks atorvastatin treatment resulted in significant reduction of circulating IL-6 concentrations, which was associated with IL-6 secretion in adipocytes (r = 0.849, P < 0.01). Meanwhile mRNA expression of PPARgamma in adipocytes was intimately related to the IL-6 secretion in adipocytes (r = -0.900, P < 0.01). Atorvastatin induced the decreased IL-6 secretion in dose-dependent mariner. Conclusions: Atorvastatin can inhibit IL-6 secretion in adipocytes possibly through upregulating PPARgamma, which may help to explain the anti-inflammatory effects of statins use. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 31 条
[21]   Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients [J].
Rezaie-Majd, A ;
Maca, T ;
Bucek, RA ;
Valent, P ;
Müller, MR ;
Husslein, P ;
Kashanipour, A ;
Minar, E ;
Baghestanian, M .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (07) :1194-1199
[22]   Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men [J].
Ridker, PM ;
Rifai, N ;
Stampfer, MJ ;
Hennekens, CH .
CIRCULATION, 2000, 101 (15) :1767-1772
[23]  
RODBELL M, 1964, J BIOL CHEM, V239, P375
[24]   Mechanisms of disease - Atherosclerosis - An inflammatory disease [J].
Ross, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :115-126
[25]   Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors [J].
Takemoto, M ;
Liao, JK .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (11) :1712-1719
[26]   Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ [J].
Trayhurn, P ;
Beattie, JH .
PROCEEDINGS OF THE NUTRITION SOCIETY, 2001, 60 (03) :329-339
[27]   INTERLEUKIN-6 - AN OVERVIEW [J].
VANSNICK, J .
ANNUAL REVIEW OF IMMUNOLOGY, 1990, 8 :253-278
[28]   Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo [J].
Weinhold, B ;
Bader, A ;
Poli, V ;
Ruther, U .
BIOCHEMICAL JOURNAL, 1997, 325 :617-621
[29]   Coming of age of C-reactive protein - Using inflammation markers in cardiology [J].
Yeh, ETH ;
Willerson, JT .
CIRCULATION, 2003, 107 (03) :370-372
[30]   Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro [J].
Zelvyte, I ;
Dominaitiene, R ;
Crisby, M ;
Janciauskiene, S .
PHARMACOLOGICAL RESEARCH, 2002, 45 (02) :147-154